Thornburg Investment Management Inc. Purchases 11,840 Shares of Cytokinetics, Incorporated $CYTK

Thornburg Investment Management Inc. grew its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 16.2% in the 3rd quarter, Holdings Channel.com reports. The firm owned 84,719 shares of the biopharmaceutical company’s stock after purchasing an additional 11,840 shares during the quarter. Thornburg Investment Management Inc.’s holdings in Cytokinetics were worth $4,656,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. UMB Bank n.a. grew its position in Cytokinetics by 10.6% during the third quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company’s stock valued at $97,000 after buying an additional 169 shares during the period. Fifth Third Bancorp increased its stake in shares of Cytokinetics by 32.3% in the 3rd quarter. Fifth Third Bancorp now owns 1,072 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 262 shares in the last quarter. Teacher Retirement System of Texas raised its holdings in Cytokinetics by 1.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 30,514 shares of the biopharmaceutical company’s stock worth $1,008,000 after purchasing an additional 341 shares during the period. Thrivent Financial for Lutherans lifted its position in Cytokinetics by 1.6% during the second quarter. Thrivent Financial for Lutherans now owns 28,119 shares of the biopharmaceutical company’s stock valued at $929,000 after purchasing an additional 449 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its position in Cytokinetics by 68.4% in the third quarter. Farther Finance Advisors LLC now owns 1,115 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 453 shares in the last quarter.

Insider Transactions at Cytokinetics

In related news, EVP Andrew Callos sold 15,000 shares of the business’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $61.93, for a total value of $928,950.00. Following the sale, the executive vice president directly owned 50,440 shares in the company, valued at approximately $3,123,749.20. The trade was a 22.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Wendell Wierenga sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $66.14, for a total value of $1,322,800.00. Following the transaction, the director owned 32,444 shares of the company’s stock, valued at $2,145,846.16. This represents a 38.14% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 151,385 shares of company stock valued at $9,817,158. 2.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CYTK. Needham & Company LLC lifted their price objective on Cytokinetics from $84.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytokinetics in a report on Wednesday, January 21st. Citigroup reiterated a “market outperform” rating on shares of Cytokinetics in a research report on Monday, December 22nd. Truist Financial raised their price objective on shares of Cytokinetics from $84.00 to $92.00 and gave the company a “buy” rating in a research report on Tuesday, February 3rd. Finally, Morgan Stanley set a $90.00 target price on shares of Cytokinetics in a research note on Thursday, January 8th. Seventeen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Cytokinetics presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.83.

Key Headlines Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: FDA approval and accelerated launch plans for Myqorzo bolster the company’s commercial outlook and cash-driven runway for 2026 catalysts. CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans
• Positive Sentiment: Several sell‑side analysts raised price targets or reiterated outperform/buy views (Citizens JMP to $96, Needham to $85, Leerink to $84), signaling continued institutional bullishness on longer‑term commercial upside. Benzinga coverage of analyst moves
• Neutral Sentiment: HC Wainwright continues to carry a “Buy” rating and a high $136 price target — a constructive endorsement for longer-term upside even as its near-term estimates changed.
• Neutral Sentiment: Reported cash balance (~$1.22B) provides financial runway to support Myqorzo commercialization and development activities, reducing near‑term liquidity risk.
• Negative Sentiment: Q4 results showed a wider-than-expected loss (reported EPS -$1.50 vs. -$1.48 expected) and rising expenses tied to launch activity, which coincided with an intraday share decline. Cytokinetics Stock Price Down Following Weak Earnings
• Negative Sentiment: HC Wainwright materially lowered FY2026–FY2028 EPS forecasts (e.g., FY2026 to -$7.12, FY2027 to -$5.12, FY2028 to -$1.67 and quarterly EPS updates), reflecting higher near-term spend for commercialization and pulling forward losses — a negative near-term earnings outlook despite the maintained Buy rating.
• Neutral Sentiment: Reported short interest data in late Feb showed anomalous/zero figures and is not providing a clear signal for near‑term positioning.

Cytokinetics Price Performance

Cytokinetics stock opened at $62.63 on Friday. Cytokinetics, Incorporated has a 1 year low of $29.31 and a 1 year high of $70.98. The firm’s 50 day moving average price is $64.21 and its 200-day moving average price is $58.38. The stock has a market cap of $7.66 billion, a P/E ratio of -9.59 and a beta of 0.54.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The company had revenue of $17.76 million for the quarter, compared to the consensus estimate of $8.02 million. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period last year, the firm earned ($1.26) earnings per share. As a group, equities analysts expect that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.